Get started
Author

Norihiko Sugisawa

Histone methylation status of H3K4me3 and H3K9me3 under methionine restriction is unstable in methionine-addicted cancer cells, but stable in normal cells
2020 · Jun Yamamoto, Qinghong Han, et al. · Biochemical and Biophysical Research Communications · 121
Linkage of methionine addiction, histone lysine hypermethylation, and malignancy
2022 · Jun Yamamoto, Sachiko Inubushi, et al. · iScience · 86
PDF
Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model
2018 · TAKASHI HIGUCHI, KEI KAWAGUCHI, et al. · Anticancer Research · 73
PDF
Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma
2019 · TAKASHI HIGUCHI, HIROMICHI OSHIRO, et al. · Anticancer Research · 50
PDF
Reversion from Methionine Addiction to Methionine Independence Results in Loss of Tumorigenic Potential of Highly-malignant Lung-cancer Cells
2021 · JUN YAMAMOTO, YUSUKE AOKI, et al. · Anticancer Research · 49
Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistance–Linked ATP-Binding Cassette Transporter ABCG2
2017 · Megumi Murakami, Shinobu Ohnuma, et al. · Drug Metabolism and Disposition · 49
PDF
Oral Recombinant Methioninase Overcomes Colorectal-cancer Liver Metastasis Resistance to the Combination of 5-Fluorouracil and Oxaliplatinum in a Patient-derived Orthotopic Xenograft Mouse Model
2019 · HIROMICHI OSHIRO, YASUNORI TOME, et al. · Anticancer Research · 47
PDF
The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model
2019 · Takashi Higuchi, Norihiko Sugisawa, et al. · Cancer Chemotherapy and Pharmacology · 44
Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model
2020 · Jun Yamamoto, Kentaro Miyake, et al. · Cancer Letters · 43
Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model
2019 · Takashi Higuchi, Kentaro Miyake, et al. · Biochemical and Biophysical Research Communications · 43
Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression
2019 · Takashi Higuchi, Norihiko Sugisawa, et al. · Biomedicine & Pharmacotherapy · 38
PDF
Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model
2019 · Jun Ho Park, Ming Zhao, et al. · Biochemical and Biophysical Research Communications · 37
Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma
2018 · Kei Kawaguchi, Takashi Higuchi, et al. · Biochemical and Biophysical Research Communications · 37
PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model
2019 · TAKASHI HIGUCHI, JUN YAMAMOTO, et al. · Cancer Genomics & Proteomics · 36
PDF
Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model
2019 · TAKASHI HIGUCHI, NORIHIKO SUGISAWA, et al. · Anticancer Research · 35
PDF
Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model
2019 · TAKASHI HIGUCHI, NORIHIKO SUGISAWA, et al. · Anticancer Research · 32
PDF
Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
2021 · Norihiko Sugisawa, Takashi Higuchi, et al. · Cancer Chemotherapy and Pharmacology · 31
Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model
2019 · Takashi Higuchi, Qinghong Han, et al. · Biochemical and Biophysical Research Communications · 31
Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease
2021 · HIROMICHI OSHIRO, YASUNORI TOME, et al. · Anticancer Research · 26
PDF
Response of Triple-negative Breast Cancer Liver Metastasis to Oral Recombinant Methioninase in a Patient-derived Orthotopic Xenograft (PDOX) Model
2020 · HYE IN LIM, JUN YAMAMOTO, et al. · In Vivo · 25
PDF
The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model
2019 · Takashi Higuchi, Norihiko Sugisawa, et al. · Translational Oncology · 23
PDF
A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model
2018 · Tasuku Kiyuna, Yasunori Tome, et al. · Biochemical and Biophysical Research Communications · 23
An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model
2021 · Hiromichi Oshiro, Yasunori Tome, et al. · Scientific Reports · 22
PDF
Oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil regressed a colon cancer growing on the peritoneal surface in a patient-derived orthotopic xenograft mouse model
2019 · Jun Ho Park, Qinghong Han, et al. · Tissue and Cell · 22
Combination Methionine-methylation-axis Blockade: A Novel Approach to Target the Methionine Addiction of Cancer
2021 · TAKASHI HIGUCHI, QINGHONG HAN, et al. · Cancer Genomics & Proteomics · 21
PDF
Works count: 74
Citation count: 1,377
H-index: 22
I10-index: 39
Year
Topic
Type